Department of Obstetrics and Gynaecology, School of Clinical Science, Monash University, Melbourne, Australia.
City Fertility, Notting Hill, Australia.
Cochrane Database Syst Rev. 2023 Aug 15;8(8):CD001301. doi: 10.1002/14651858.CD001301.pub2.
Starting over 40 years ago, in vitro fertilisation (IVF) has become the cornerstone for fertility treatment. Since then, in 1992, Palermo and colleagues successfully applied the technique intracytoplasmic sperm injection (ICSI) to benefit couples where conventional in vitro fertilisation (c-IVF) and sub-zonal insemination (SUZI) proved unsuccessful. After this case report, ICSI has become the treatment of choice for couples with severe male factor subfertility. Over time, ICSI has been used in the treatment of couples with mild male and even unexplained infertility. This review is an update of the review, first published in 1999, comparing ICSI with c-IVF for couples with males presenting with normal total sperm count and motility.
To evaluate the effectiveness and safety of ICSI relative to c-IVF in couples with males presenting with normal total sperm count and motility.
We searched the following databases and trial registers: Cochrane Central Register of Controlled Trials (CENTRAL), Embase (excerpta Medica Database), MEDLINE (Medical Literature Analysis and Retrieval System Online) and PsycINFO (Psychological literature database) for articles between January 2010 and 22 February 2023.
We included randomised controlled trials (RCTs) that compared ICSI with c-IVF in couples with males presenting with normal total sperm count and motility.
We used standard methodical procedures recommended by Cochrane. The primary review outcomes were live birth and adverse events. Secondary outcomes included clinical pregnancy, viable intrauterine pregnancy and miscarriage.
The original review published in 2003 included one RCT. In this 2023 update, we identified an additional two RCTs totalling a cohort of 1539 couples, comparing ICSI with c-IVF techniques. Two studies reported on live birth. Using the GRADE method, we assessed the certainty of evidence and reported evidence as low-certainty for live birth. We are uncertain of the effect of ICSI versus c-IVF for live birth rates (risk ratio (RR) 1.11, 95% confidence interval (CI 0.94 to 1.30, I = 0%, 2 studies, n = 1124, low-certainty evidence). The evidence suggests that if the chance of live birth following c-IVF is assumed to be 32%, the chance of live birth with ICSI would be between 30% and 41%. For adverse events; multiple pregnancy, ectopic pregnancy, pre-eclampsia and prematurity, there was probably little or no difference between the two techniques. No study reported the primary outcome stillbirth. For secondary outcomes, we are uncertain of the effect of ICSI versus c-IVF for clinical pregnancy rates (RR 1.00, 95% CI 0.88 to 1.13, I = 45%, 3 studies, n = 1539, low-certainty evidence). Comparison of viable intrauterine pregnancy rates showed probably little or no difference between ICSI and c-IVF (RR 1.00, 95% CI 0.86 to 1.16, I=75%, 2 studies, n = 1479 couples, moderate-certainty evidence). The high heterogeneity may have been caused by one older study conducted when protocols were less rigorous. The evidence suggests that if the chance of viable intrauterine pregnancy following c-IVF is assumed to be 33%, the chance of viable intrauterine pregnancy with ICSI would be between 28% and 38%. Miscarriage rates also showed probably little or no difference between the two techniques.
AUTHORS' CONCLUSIONS: The current available studies that compare ICSI and c-IVF in couples with males presenting with normal total sperm count and motility, show neither method was superior to the other, in achieving live birth, adverse events (multiple pregnancy, ectopic pregnancy, pre-eclampsia and prematurity), also alongside secondary outcomes, clinical pregnancy, viable intrauterine pregnancy or miscarriage.
早在 40 多年前,体外受精(IVF)已成为生育治疗的基石。从那时起,在 1992 年,Palermo 和同事成功地将技术胞浆内精子注射(ICSI)应用于常规体外受精(c-IVF)和亚区授精(SUZI)不成功的夫妇。在这个病例报告之后,ICSI 已成为严重男性因素不育夫妇的治疗选择。随着时间的推移,ICSI 已被用于治疗轻度男性因素甚至不明原因的不育夫妇。本综述是对 1999 年首次发表的综述的更新,比较了 ICSI 与 c-IVF 对总精子计数和活力正常的男性夫妇的疗效。
评估 ICSI 相对于 c-IVF 在总精子计数和活力正常的男性夫妇中的有效性和安全性。
我们在以下数据库和试验登记处进行了检索:Cochrane 对照试验中心注册库(CENTRAL)、Embase(摘录医学数据库)、MEDLINE(医学文献分析和检索系统在线)和 PsycINFO(心理文献数据库),检索时间为 2010 年 1 月至 2023 年 2 月 22 日。
我们纳入了比较总精子计数和活力正常的男性夫妇中 ICSI 与 c-IVF 的随机对照试验(RCTs)。
我们使用了 Cochrane 推荐的标准方法学程序。主要的综述结果是活产和不良事件。次要结果包括临床妊娠、可存活宫内妊娠和流产。
原始综述于 2003 年发表,纳入了一项 RCT。在 2023 年的更新中,我们又确定了两项 RCT,共纳入了 1539 对夫妇,比较了 ICSI 与 c-IVF 技术。两项研究报告了活产。使用 GRADE 方法,我们评估了证据的确定性,并报告了低确定性证据的活产率。我们对 ICSI 与 c-IVF 对活产率的影响不确定(RR 1.11,95%置信区间(CI)0.94 至 1.30,I=0%,2 项研究,n=1124,低确定性证据)。证据表明,如果假设 c-IVF 后的活产率为 32%,那么 ICSI 的活产率可能在 30%至 41%之间。对于不良事件,多胎妊娠、异位妊娠、子痫前期和早产,两种技术之间可能差异不大或没有差异。没有研究报告主要结局死产。对于次要结局,我们对 ICSI 与 c-IVF 对临床妊娠率的影响不确定(RR 1.00,95%置信区间(CI)0.88 至 1.13,I=45%,3 项研究,n=1539,低确定性证据)。比较可存活宫内妊娠率,ICSI 与 c-IVF 之间可能差异不大或没有差异(RR 1.00,95%置信区间(CI)0.86 至 1.16,I=75%,2 项研究,n=1479 对夫妇,中等确定性证据)。高异质性可能是由一项较旧的研究引起的,当时方案不太严格。证据表明,如果假设 c-IVF 后可存活宫内妊娠的几率为 33%,那么 ICSI 后可存活宫内妊娠的几率将在 28%至 38%之间。流产率也显示两种技术之间可能差异不大或没有差异。
目前比较 ICSI 和 c-IVF 在总精子计数和活力正常的男性夫妇中的研究显示,两种方法在实现活产、不良事件(多胎妊娠、异位妊娠、子痫前期和早产)方面都没有优势,同时还有次要结局,包括临床妊娠、可存活宫内妊娠或流产。